Literature DB >> 16044204

Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success.

Lesley-Ann M Hanson1, Jane A Schulz, Catherine G Flood, Bonita Cooley, Florence Tam.   

Abstract

OBJECTIVE: An aging population has resulted in higher prevalence of urinary incontinence (UI) and pelvic organ prolapse (POP). This study examines a nurse-run clinic and analyzes the factors contributing to successful pessary use. STUDY
DESIGN: A retrospective chart review of 1,216 patients was completed. History, pelvic examination and pessary fitting was done. Data was analyzed utilizing a categorical model of maximum-likelihood estimation to investigate relationships.
RESULTS: Median patient age was 63 years. Median number of pessaries tried was two. Eighty-five percent of post-menopausal women were on hormone replacement therapy (HRT) prior to fitting. Highest success rate of 78% was in the group on both systemic and local HRT. Success rates ranged from 58% for urge incontinence to 83% for uterine prolapse. Prior vaginal surgery was a factor impacting success. In our series highest success rates for fitting were obtained with ring pessaries, ring with support, and gellhorns.
CONCLUSIONS: This model is a viable, option for the conservative management of UI and POP. Local HRT plays an important role in successful pessary fitting. Complications are rare.

Entities:  

Mesh:

Year:  2005        PMID: 16044204     DOI: 10.1007/s00192-005-1362-x

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  11 in total

1.  Gynecologists' patterns of prescribing pessaries.

Authors:  E Pott-Grinstein; J R Newcomer
Journal:  J Reprod Med       Date:  2001-03       Impact factor: 0.142

Review 2.  Nonsurgical management of genital prolapse. A review and recommendations for clinical practice.

Authors:  P A Poma
Journal:  J Reprod Med       Date:  2000-10       Impact factor: 0.142

3.  Videocystourethrography with a ring pessary in situ. A clinically useful preoperative investigation for continent women with urogenital prolapse?

Authors:  A Hextall; K Boos; L Cardozo; P Toozs-Hobson; K Anders; V Khullar
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

4.  Static and dynamic MRI of a urinary control intra-vaginal device.

Authors:  A J Maubon; M P Boncoeur-Martel; V Juhan; C R Courtieu; A S Thurmond; P Aubas; P Marès; J P Rouanet
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

5.  Vaginal prolapse: management with nonsurgical techniques.

Authors:  G W Davila
Journal:  Postgrad Med       Date:  1996-04       Impact factor: 3.840

6.  Vaginal pessaries and their use in pelvic relaxation.

Authors:  P J Sulak; T J Kuehl; B L Shull
Journal:  J Reprod Med       Date:  1993-12       Impact factor: 0.142

Review 7.  Pessary placement and management.

Authors:  M V Palumbo
Journal:  Ostomy Wound Manage       Date:  2000-12       Impact factor: 2.629

8.  Prevention of exercise incontinence with mechanical devices.

Authors:  I Nygaard
Journal:  J Reprod Med       Date:  1995-02       Impact factor: 0.142

Review 9.  The demography of menopause.

Authors:  K Hill
Journal:  Maturitas       Date:  1996-03       Impact factor: 4.342

10.  Pessary test in women with urinary incontinence.

Authors:  N N Bhatia; A Bergman
Journal:  Obstet Gynecol       Date:  1985-02       Impact factor: 7.661

View more
  33 in total

1.  Pessary use in pelvic organ prolapse and urinary incontinence.

Authors:  Keisha A Jones; Oz Harmanli
Journal:  Rev Obstet Gynecol       Date:  2010

2.  Lajjalu treatment of uterine prolapse.

Authors:  T M Shivanandaiah; T M Indudhar
Journal:  J Ayurveda Integr Med       Date:  2010-04

Review 3.  An integrative review and severity classification of complications related to pessary use in the treatment of female pelvic organ prolapse.

Authors:  Marwa Abdulaziz; Lynn Stothers; Darren Lazare; Andrew Macnab
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

4.  The effectiveness of supportive underwear in women with pelvic organ prolapse: a pilot study.

Authors:  Karin Lammers; Mark E Vierhout; Mariëlla I J Withagen; Kirsten B Kluivers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-07-17

5.  Diagnosis and Therapy of Female Pelvic Organ Prolapse. Guideline of the DGGG, SGGG and OEGGG (S2e-Level, AWMF Registry Number 015/006, April 2016).

Authors:  K Baeßler; T Aigmüller; S Albrich; C Anthuber; D Finas; T Fink; C Fünfgeld; B Gabriel; U Henscher; F H Hetzer; M Hübner; B Junginger; K Jundt; S Kropshofer; A Kuhn; L Logé; G Nauman; U Peschers; T Pfiffer; O Schwandner; A Strauss; R Tunn; V Viereck
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-12       Impact factor: 2.915

Review 6.  Pessaries (mechanical devices) for pelvic organ prolapse in women.

Authors:  Carol Bugge; Elisabeth J Adams; Deepa Gopinath; Fiona Reid
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  Symptoms, quality of life, and factors affecting women's treatment decisions regarding pelvic organ prolapse.

Authors:  Symphorosa Shing Chee Chan; Rachel Yau Kar Cheung; Ka Wah Yiu; Lai Loi Lee; Albe Wai Lam Pang; Tony Kwok Hung Chung
Journal:  Int Urogynecol J       Date:  2012-03-08       Impact factor: 2.894

8.  A retrospective comparison of ring pessary and multicomponent behavioral therapy in managing overactive bladder.

Authors:  Eddie H M Sze; Gerry Hobbs
Journal:  Int Urogynecol J       Date:  2014-05-07       Impact factor: 2.894

9.  Pessary types and discontinuation rates in patients with advanced pelvic organ prolapse.

Authors:  Birte Wolff; Kathryn Williams; Allen Winkler; Lawrence Lind; Dara Shalom
Journal:  Int Urogynecol J       Date:  2016-12-10       Impact factor: 2.894

10.  Patterns of pessary care and outcomes for medicare beneficiaries with pelvic organ prolapse.

Authors:  Marianna Alperin; Aqsa Khan; Emily Dubina; Christopher Tarnay; Ning Wu; Chris L Pashos; Jennifer T Anger
Journal:  Female Pelvic Med Reconstr Surg       Date:  2013 May-Jun       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.